PluriStem Therapeutics Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed by PluriStem Therapeutics Inc. on May 9, 2012. The company, incorporated in Nevada, is based in Haifa, Israel, and focuses on developing cell-based therapies. The report addresses a specific clinical event under Item 8.01 (Other Events).
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure and does not contain financial statements.
Material Changes and Clinical Update
The primary material event reported is a positive clinical outcome announced via press release on May 9, 2012. A seven-year-old girl suffering from aplastic bone marrow, whose condition was rapidly deteriorating, experienced a reversal of her condition following an intramuscular injection of the company's PLacental eXpanded (PLX) cells. The report notes a significant increase in the patient's red cells, white cells, and platelets.
Guidance, Outlook, and Risks
The filing does not provide updated financial guidance, management commentary on future operations, or a discussion of risks and contingencies beyond the specific clinical event. No unusual items or contingencies were disclosed in this text.
Key Facts for Investor Verification
- Verify the full details of the press release regarding the seven-year-old patient's treatment with PLX cells.
- Confirm the regulatory status of the PLX cell therapy and the nature of the clinical trial or compassionate use protocol.
- Review subsequent filings for any financial impact or strategic shifts resulting from this clinical data.
- Check for any additional patient data or peer-reviewed publications related to this case.